Prostate Cancer

A Community-Based Prostate Cancer Screening and Education Program for Asian American Men in Medically Underserved Communities.

This study analyzed data from a community-based prostate cancer (PCa) education and screening program (Prostate Outreach Project; POP) to enhance PCa-related knowledge among medically underserved Asian American men.

Synergistic Activity of DNA Damage Response Inhibitors in Combination with Radium-223 in Prostate Cancer.

Radium-223 (223Ra) and Lutetium-177-labelled-PSMA-617 (177Lu-PSMA) are currently the only radiopharmaceutical treatments to prolong survival for patients with metastatic-castration-resistant prostate cancer (mCRPC); however, mCRPC remains an aggressive disease.

Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence.

To evaluate the clinical outcome in men with recurrent prostate cancer (PCa) treated by salvage radiotherapy (sRT) prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT)-guided.

Assessment of PSMA Expression of Healthy Organs in Different Stages of Prostate Cancer Using [68Ga]Ga-PSMA-11-PET Examinations.

The efficacy of radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) is currently being investigated for its application in patients with early-stage prostate cancer (PCa). However, little is known about PSMA expression in healthy organs in this cohort.

The Added Value of Side-specific Systematic Biopsy in Patients Diagnosed by Magnetic Resonance Imaging-targeted Prostate Biopsy - Beyond the Abstract

The combination of systematic biopsy and MRI-targeted biopsy remains recommended due to the risk of overlooking clinically significant prostate cancer. Omitting systematic biopsy is associated with the risk of missing clinically significant PCa and reduced ISUP concordance at radical prostatectomy. However, in the era of minimally invasive procedures, their role has been increasingly debated considering their suggested marginal added value with the evolution of MRI and biopsy technology.

Impact of Prostate Size on the Functional and Oncological Outcomes of Robot-assisted Radical Prostatectomy - Beyond the Abstract

This paper investigates the impact of prostate size on the functional and oncological outcomes of Robotic-assisted Radical Prostatectomy (RARP). The study, conducted by a single surgeon over a substantial period, involves a large cohort of 14,481 patients, making it one of the most comprehensive investigations on this subject in the existing literature.

Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.

The cT1a vs. cT1b substratification was introduced in 1992 but never formally tested since. We tested the discriminative ability of cT1a vs. cT1b substaging on cancer-specific survival (CSS) in contemporary incidental prostate cancer (PCa) patients.

Real-world treatment patterns and medical costs of prostate cancer patients in Switzerland - A claims data analysis.

Prostate cancer (PC) is the most prevalent cancer in men in Switzerland. However, evidence on the real-world health care use of PC patients is scarce. The aim of this study is to describe health care utilization, treatment patterns, and medical costs in PC patients over a period of five years (2014-2018).

Comparative Effectiveness of Partial Gland Cryoablation Versus Robotic Radical Prostatectomy for Cancer Control.

There is an absence of high-level evidence comparing oncologic endpoints for partial gland ablation, and most series use prostate-specific antigen (PSA) rather than biopsy endpoints. Our aim was to compare oncologic outcomes between partial gland cryoablation (PGC) and radical prostatectomy (RP) for prostate cancer.

A systematic review of cytoreductive prostatectomy outcomes and complications in oligometastatic disease.

To analyze outcomes and complications of cytoreductive prostatectomy (CRP) for oligometastatic prostate cancer (PCa) in order to elucidate its role in this space.

We performed a systematic literature search using three databases (Medline, Scopus, and Web of Science).